KalVista Pharmaceuticals, Inc. announced the presentation of a novel analysis characterizing hereditary angioedema attacks occurring in patients receiving long-term prophylaxis treatments at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference in Singapore.
